A new study in pancreatic ductal adenocarcinoma (PDAC), where almost 80% of cases are KRAS mutant, demonstrated that activating mutation in KRAS alone is sufficient to elevate levels of CD73 suggesting that CD73 induction with oncogenes extends beyond lung cancer (78). This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.